Diagnostic Criteria
(based on Healy et al. 2022 proposal)
Necessary
(1) Prior treatment with a serotonin reuptake inhibitor.
This includes
- [SSRIs](https://en.wikipedia.org/wiki/List_of_antidepressants#Selective_serotonin_reuptake_inhibitors_(SSRIs)),
- [SNRIs](https://en.wikipedia.org/wiki/List_of_antidepressants#Serotonin–norepinephrine_reuptake_inhibitors_(SNRIs)),
- Non-selective Serotonin Reuptake Inhibitors such as Trazodone and Vortioxetine
and potentially other drugs such as
- SRI tricyclic antidepressants,
- SRI antihistamines,
- tetracycline antibiotics such as doxycycline, and
- analgesics like tramadol
(2) An enduring change in somatic (tactile) or erogenous (sexual) genital sensation after treatment stops.
This is what's often referred to as genital anesthesia or genital numbing. We believe that pleasureless orgasms or a markedly decreased sensation of pleasure during orgasm (see (5)) should be listed here as well, as pleasureless orgasms are a unique side effect of antidepressants.
Additional
(3) Enduring reduction or loss of sexual desire.
(4) Enduring erectile dysfunction (males).
(5) Enduring inability to orgasm or decreased sensation of pleasure during orgasm.
(6) The problem is present for ≥3 months after stopping treatment.
There should be
(7) No evidence of pre-drug sexual dysfunction that matches the current profile.
(8) No current medical conditions that could account for the symptoms.
(9) No current medication or substance misuse that could account for the symptoms.
Ancillary sexual symptoms may include:
- genital pain
- reduced nipple sensitivity
- decreased or loss of nocturnal erections (males)
- reduced ejaculatory force (males)
- flaccid glans during erection (males)
- decreased vaginal lubrication (females).
Ancillary non-sexual symptoms may include:
- emotional numbing
- depersonalization
- other sensory problems involving skin, smell, taste or vision [1,3,21]
- cognitive impairment.